Skip to main content

Table 3 Treatment outcomes in patients with each sequential chemotherapy

From: Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

  FFX-GnP (n = 120) GnP-FFX (n = 61) P value FFX-GnP (n = 53) GnP-FFX (n = 59) P value
Treatment duration (months) 12.0 (7.6–18.1) 11.7 (7.6–19.4) 0.945 12.0 (8.0–22.3) 11.7 (7.4–20.0) 0.714
Best response in second-line treatment    0.86    0.69
 CR 1 (0.8) 0 (0)   1 (1.9) 0 (0)  
 PR 19 (15.8) 10 (16.4)   7 (13.2) 10 (16.9)  
 SD 61 (50.8) 29 (47.5)   27 (50.9) 28 (47.5)  
 PD 39 (32.5) 22 (36.1)   18 (34.0) 21 (35.6)  
Response rates in second-line treatment
 DCR 81 (67.5) 39 (63.9) 0.631 35 (66.0) 38 (64.4) 0.86
 ORR 20 (16.7) 10 (16.4) 0.963 8 (15.1) 10 (16.9) 0.79
Third-line chemotherapy 47 (39.2) 29 (47.5) 0.508 16 (30.2) 28 (47.5) 0.14
 Other 5-FUa 46 6   1 6  
 Other gemcitabineb 1 21   15 20  
 Other (clinical trial, SBRT) 0 2   0 2  
  1. FFX FOLFIRINOX, GnP gemcitabine plus nab-paclitaxel, AEs adverse events, CR complete response, PR partial response, SD stable disease, PD progression of disease, ORR objective response rate, DCR disease control rate, 5-FU 5-fluorouracil, SBRT stereotactic body radiotherapy, NAPOLI nanoliposomal irinotecan plus 5-FU/lecovorin, iFAM infusional 5-FU plus doxorubicin and mitomycin-C
  2. aIncluded the NAPOLI, iFAM, tegafur/gimestat/otastat potassium, capecitabine, and CCRT with 5-FU or capecitabine regimens
  3. bIncluded gemcitabine, gemcitabine plus erlotinib